TELA Bio, Inc.
TELATELA Bio, Inc. in brief
TELA Bio, Inc. is a listed company in the Medical Equipment industry, based in Malvern, Pennsylvania, USA. It was founded in 2012. Its market value was $52 M on 6 October 2026, which makes it the 21,183rd largest listed company in the world and the 3,843rd largest in the USA on this site. In the year to December 2025 it had sales of $80 M and a net loss of $39 M. It employs about 218 people and Heather C. Getz is its chief executive. Its largest business segments by sales in 2025 were Single reportable segment (100%). Its shares trade under the symbol TELA (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About TELA Bio, Inc.
We are a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy. Our growing product portfolio is purposefully designed to leverage the patient’s natural healing response while minimizing long-term exposure to permanent synthetic materials. We are committed to delivering our advanced technologies with a strong economic value proposition to assist surgeons and institutions in providing next-generation soft-tissue repair solutions to more patients worldwide.
From the company's annual report filed with the US SEC: read the report
TELA Bio, Inc. timeline
- 2012
- 🏁· approximateFounded
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2019
- 🔔Initial public offering on NasdaqFinal prospectus filed with the SEC on 8 November 2019; shares registered for exchange trading on 7 November 2019.
- 2025
- 💰Record revenue of $80 millionFY2025, the highest of the 8 years on record.
Events of TELA Bio, Inc. from the company record, SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #3,455 (Jan 2020) · #3,176 (Jan 2021) · #3,947 (Jan 2022) · #3,596 (Dec 2022) · #3,473 (Jul 2023) · #3,379 (Jan 2024) · #2,213 (Mar 2026) · #3,878 (Aug 2026) · #3,824 (Oct 2026)
Key ratios
- P/E ratio (TTM)
- n/m (loss)
- Price / sales (TTM)
- 0.7×
- Price / book
- 8.2×
- Free cash flow yield
- -55.7%
- Net margin (TTM)
- -53.6%
- Operating margin
- -42.1%
- Return on equity
- -663.7%
- Liabilities / assets
- 92.2%
- Net debt
- $5M
- Revenue growth
- +15.8%
- R&D / revenue
- 11.5%
- Revenue per employee
- $368 K
- Profit per employee
- $-178 K
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $80M | +15.8% | $-34M | $-39M | -48.4% |
| Dec 2024 | $69M | +18.6% | $-34M | $-38M | -54.6% |
| Dec 2023 | $58M | +41.1% | $-44M | $-47M | -79.8% |
| Dec 2022 | $41M | +40.6% | $-39M | $-44M | -107.0% |
| Dec 2021 | $29M | +61.8% | $-29M | $-33M | -113.0% |
| Dec 2020 | $18M | +17.9% | $-25M | $-29M | -158.1% |
| Dec 2019 | $15M | +86.8% | $-19M | $-22M | -145.1% |
| Dec 2018 | $8M | — | $-18M | $-21M | -255.0% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-28M | $0M | $-29M | $-0.83 | — |
| Dec 2024 | $-42M | $1M | $-43M | $-1.33 | — |
| Dec 2023 | $-41M | $1M | $-41M | $-2.04 | — |
| Dec 2022 | $-41M | $1M | $-42M | $-2.72 | — |
| Dec 2021 | $-30M | $1M | $-31M | $-2.30 | — |
| Dec 2020 | $-24M | $0M | $-25M | $-2.23 | — |
| Dec 2019 | $-26M | $0M | $-26M | $-17.10 | — |
| Dec 2018 | $-20M | $0M | $-20M | $-101.41 | — |
Quarterly results
Latest quarter to Sep 2026: revenue $19M (-8.4% on a year earlier), net income $-9M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 10, 202610-QQuarterly report · period to Sep 2026
- Nov 10, 20268-KCurrent reportResults of operations
- Oct 8, 20268-KCurrent reportShareholder vote
- Oct 6, 20268-KCurrent reportOther events
- Oct 5, 20268-KCurrent reportOther events
- Sep 29, 20268-KCurrent reportMaterial agreement
- Sep 18, 20268-KCurrent reportListing notice
- Sep 14, 2026DEF 14AProxy statement
- Aug 31, 20268-KCurrent reportRestructuring costs · Directors or officers changed · Regulation FD disclosure
- Aug 13, 20268-K/ACurrent report (amended)Directors or officers changed
- Aug 11, 202610-QQuarterly report · period to Jun 2026
- Aug 10, 20268-KCurrent reportResults of operations
Official filings of TELA Bio, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $80 M
- Operating income
- $-34 M
- Net income
- $-39 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $81 M
- Total liabilities
- $75 M
- Total equity
- $6 M
As of December-2025
Top 48 institutional investors in TELA Bio, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Essex Woodlands Management, Inc. | 7,714,709 | 0 (0.00%) | 17.07% | $9 M | Nov 6, 2026 |
| 2 | Nantahala Capital Management, LLC | 6,545,596 | -5,242,632 (-44.47%) | 14.49% | $8 M | Nov 13, 2026 |
| 3 | Silverarc Capital Management, LLC | 2,137,201 | 0 (0.00%) | 4.73% | $2 M | Nov 12, 2026 |
| 4 | Perkins Capital Management Inc | 2,082,391 | +707,349 (+51.44%) | 4.61% | $2 M | Nov 2, 2026 |
| 5 | Vanguard Capital Management LLC | 1,568,218 | 0 (0.00%) | 3.47% | $2 M | Nov 13, 2026 |
| 6 | DAFNA Capital Management LLC | 1,441,029 | 0 (0.00%) | 3.19% | $2 M | Nov 16, 2026 |
| 7 | Up Strategic Wealth Investment Advisors LLC | 641,556 | +541,668 (+542.28%) | 1.42% | $1 M | Nov 12, 2026 |
| 8 | Sio Capital Management, LLC | 636,300 | 0 (0.00%) | 1.41% | $1 M | Nov 16, 2026 |
| 9 | WealthTrust Axiom LLC | 550,128 | +92,394 (+20.19%) | 1.22% | $1 M | Nov 10, 2026 |
| 10 | Geode Capital Management, LLC | 412,662 | +23,439 (+6.02%) | 0.91% | $0 M | Nov 6, 2026 |
| 11 | White Pine Capital LLC | 405,664 | New | 0.90% | $0 M | Nov 9, 2026 |
| 12 | BlackRock, Inc. | 374,516 | 0 (0.00%) | 0.83% | $0 M | Nov 13, 2026 |
| 13 | Landscape Capital Management, L.L.C. | 307,645 | New | 0.68% | $0 M | Nov 10, 2026 |
| 14 | Vanguard Fiduciary Trust Co | 213,138 | 0 (0.00%) | 0.47% | $0 M | Nov 13, 2026 |
| 15 | HRT Financial LP | 126,162 | New | 0.28% | $0 M | Nov 13, 2026 |
| 16 | Marshall Wace, LLP | 122,237 | New | 0.27% | $0 M | Nov 13, 2026 |
| 17 | Citadel Advisors LLC | 104,467 | New | 0.23% | $0 M | Nov 16, 2026 |
| 18 | Wavvest Wealth LLC | 83,524 | — | 0.18% | $0 M | Oct 21, 2026 |
| 19 | Jane Street Group, LLC | 81,737 | +32,492 (+65.98%) | 0.18% | $0 M | Nov 12, 2026 |
| 20 | Northern Trust Corp | 74,790 | 0 (0.00%) | 0.17% | $0 M | Nov 16, 2026 |
| 21 | Morgan Stanley | 70,000 | +69,963 (+189089.19%) | 0.15% | $0 M | Nov 13, 2026 |
| 22 | Raymond James Financial Inc | 67,700 | 0 (0.00%) | 0.15% | $0 M | Nov 12, 2026 |
| 23 | State Street Corp | 63,383 | 0 (0.00%) | 0.14% | $0 M | Nov 12, 2026 |
| 24 | Ducere Wealth Management LLC | 57,766 | +6,766 (+13.27%) | 0.13% | $0 M | Nov 13, 2026 |
| 25 | PNC Financial Services Group, Inc. | 53,612 | 0 (0.00%) | 0.12% | $0 M | Nov 6, 2026 |
Show all 48: investors 26 to 48
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Destiny Wealth Partners, LLC | 52,500 | 0 (0.00%) | 0.12% | $0 M | Nov 5, 2026 |
| 27 | Atom Investors LP | 35,891 | +20,418 (+131.96%) | 0.08% | $0 M | Nov 16, 2026 |
| 28 | StoneX Group Inc. | 30,000 | New | 0.07% | $0 M | Nov 3, 2026 |
| 29 | Rollins Financial Advisors, LLC | 28,735 | New | 0.06% | $0 M | Nov 10, 2026 |
| 30 | Mercer Global Advisors Inc /adv | 25,988 | +11,160 (+75.26%) | 0.06% | $0 M | Nov 16, 2026 |
| 31 | Susquehanna International Group, LLP | 25,133 | New | 0.06% | $0 M | Nov 16, 2026 |
| 32 | Great Valley Advisor Group, Inc. | 23,602 | +4,000 (+20.41%) | 0.05% | $0 M | Nov 9, 2026 |
| 33 | TD Waterhouse Canada Inc. | 23,000 | 0 (0.00%) | 0.05% | $0 M | Oct 16, 2026 |
| 34 | Primoris Wealth Advisors, LLC | 20,300 | 0 (0.00%) | 0.04% | $0 M | Oct 28, 2026 |
| 35 | XTX Topco Ltd | 19,226 | -10,332 (-34.96%) | 0.04% | $0 M | Nov 16, 2026 |
| 36 | J.W. Cole Advisors, Inc. | 16,250 | 0 (0.00%) | 0.04% | $0 M | Nov 5, 2026 |
| 37 | UBS Group AG | 15,756 | -17,710 (-52.92%) | 0.03% | $0 M | Nov 10, 2026 |
| 38 | HighTower Advisors, LLC | 11,200 | 0 (0.00%) | 0.02% | $0 M | Nov 10, 2026 |
| 39 | Vanguard Global Advisers, LLC | 4,604 | 0 (0.00%) | 0.01% | $0 M | Nov 13, 2026 |
| 40 | Wells Fargo & Company/mn | 4,317 | +117 (+2.79%) | 0.01% | $0 M | Nov 16, 2026 |
| 41 | Citigroup Inc | 3,039 | +1,265 (+71.31%) | 0.01% | $0 M | Nov 4, 2026 |
| 42 | Jpmorgan Chase & Co | 1,089 | +1,050 (+2692.31%) | 0.00% | $0 M | Nov 12, 2026 |
| 43 | Steward Partners Investment Advisory, LLC | 995 | -996 (-50.03%) | 0.00% | $0 M | Nov 13, 2026 |
| 44 | Simplex Trading, LLC | 644 | -632 (-49.53%) | 0.00% | $0 M | Nov 4, 2026 |
| 45 | SBI Securities Co., Ltd. | 301 | 0 (0.00%) | 0.00% | $0 M | Oct 22, 2026 |
| 46 | BNP Paribas Financial Markets | 210 | 0 (0.00%) | 0.00% | $0 M | Nov 12, 2026 |
| 47 | Royal Bank Of Canada | 61 | +2 (+3.39%) | 0.00% | $0 M | Nov 16, 2026 |
| 48 | Barclays PLC | 6 | -202 (-97.12%) | 0.00% | $0 M | Nov 6, 2026 |
Mutual funds holding TELA Bio, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 1.15 M | $1 M | 3.4% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 389,470 | $0 M | 1.2% | <0.01% | −0.4% | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 216,620 | $0 M | 0.65% | <0.01% | +26% | May 31, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 66,813 | $0 M | 0.20% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 55,409 | $0 M | 0.17% | <0.01% | +33% | May 31, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 29,070 | $0 M | 0.09% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 18,634 | $0 M | 0.06% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Knights of Columbus U.S. ALL CAP INDEX FUNDKnights of Columbus Asset Advisors LLC | 230 | $0 M | <0.01% | <0.01% | +7.5% | Jul 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 8 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at TELA Bio, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | William J. PlovanicDirector | Grant or award | +16,089 | $1.010 | $16 K | 60,619 | Form 4 |
| filed | Joseph H. CapperDirector | Grant or award | +19,801 | $1.010 | $20 K | 199,628 | Form 4 |
| filed | Joseph H. CapperDirector | Buy | +25,000 | $1.220 | $31 K | 179,827 | Form 4 |
| filed | Joseph H. CapperDirector | Buy | +50,000 | $1.170 | $59 K | 154,827 | Form 4 |
| filed | Joseph H. CapperDirector | Buy | +50,000 | $1.060 | $53 K | 104,827 | Form 4 |
| filed | Joseph H. CapperDirector | Buy | +25,000 | $1.020 | $26 K | 54,827 | Form 4 |
| filed | Heather C. GetzChief Executive Officer, Director | Buy | +12,500 | $0.660 | $8 K | 532,500 | Form 4 |
| filed | Heather C. GetzChief Executive Officer, Director | Buy | +15,000 | $0.700 | $11 K | 520,000 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: TELA Bio, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 1-for-25 reverse split
Fails to deliver
- : 2,444 shares at $1.14
- : 7,271 shares at $1.30
- : 2,084 shares at $1.30
- : 16,788 shares at $1.25
- : 6,087 shares at $1.18
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
TELA Bio, Inc. scorecard#
Passes 6 of the 21 checks that could be worked out: strongest in growth (3 of 6), weakest in valuation (1 of 5). Fiscal year 2025; market cap of Oct 6, 2026.
Valuation1 of 5
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✗Price to book below its peers' median8.2×Price to book 8.2× against Healthcare's median of 3.1×.
- ✓Price to sales below its peers' median0.7×Price to sales 0.7× against Healthcare's median of 3.8×.
- ✗Free cash flow yield above 5%-55.7%Free cash flow is -55.7% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth3 of 6
- ✓Revenue grew in the newest year15.8%Revenue up 15.8% in fiscal 2025.
- ✓Revenue up more than 5% a year over three years24.7%24.7% a year over the three years to fiscal 2025.
- ✗Faster growth over three years than its peers' median24.7%24.7% a year against Medical Equipment's median of 24.7% (5 companies).
- ✗Earnings per share grew in the newest year-0.83 vs -1.33Diluted EPS -0.83 in fiscal 2025 against -1.33 the year before (report's currency).
- ✗Net income higher than five years earlier-$39 M-$39 M in fiscal 2025 against -$29 M in 2020.
- ✓Revenue rose in at least four of the last five years5 of 5Revenue rose in 5 of the five years to fiscal 2025.
Profitability1 of 5
- ✗Profitable in the newest year-$39 MNet income -$39 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- ✗Operating margin above its peers' median-42.0%-42.0% against Medical Equipment's median of -38.5% (8 companies).
- ✗Return on equity above 15%-223.3%-223.3% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- ✓Operating margin wider than three years earlier-42.0%-42.0% in fiscal 2025 against -94.2% in 2022.
Financial health1 of 4
- ✓Short-term assets cover short-term liabilities4.2×Current ratio 4.20 at the end of fiscal 2025.
- ✗Debt below equity8.8×Debt to equity 8.82 at the end of fiscal 2025.
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- ✗Altman Z-score outside the distress zone-5.96Z-score -5.96 (distress zone) for fiscal 2025.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year64.6%Diluted shares up 64.6% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Medical Equipment, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from TELA Bio, Inc.'s statements, beside the median of Medical Equipment.
| Ratio | Trend | 2025 | Median of peers |
|---|---|---|---|
| Operating margin | -42.1% | -38.5% | |
| Net margin | -48.4% | -44.9% | |
| Return on equity | -223.4% | -94.5% | |
| Revenue growth, 3 years a year | 24.7% | 24.7% | |
| Revenue growth | 15.8% | 15.6% | |
| Debt to equity | 8.82× | — |
3of 9on the Piotroski tests of financial strength
- Net loss of $39 million, the 9th loss-making year in a row.
- Free cash flow was negative: -$29 million.
- The share count rose 64.6% in the year.
- Revenue has grown 8 years in a row.
TELA Bio, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 80+15.8%100% | 69+18.6%100% | 58+41.1%100% | 41+40.6%100% | 29+61.8%100% | 18+17.9%100% | 15+86.7%100% | 8.3+94.9%100% | 4.2—100% | |
| Gross profit | 54+16.9%67.7% | 46+15.9%67.1% | 40+48.3%68.6% | 27+43.8%65.3% | 19+67.5%63.9% | 11+21.2%61.7% | 9.3+215%60.0% | 2.9+16.2%35.6% | 2.5—59.6% | |
| Research and development | 9.2+4.6%11.5% | 8.8−8.4%12.7% | 9.6+7.6%16.5% | 8.9+32.5%21.6% | 6.7+58.5%22.9% | 4.3+2.5%23.4% | 4.2−4.3%26.9% | 4.3−25.0%52.4% | 5.8—136% | |
| Selling and marketing | 63−2.3%78.7% | 65+8.3%93.3% | 60+38.0%102% | 43+48.8%104% | 29+31.4%98.6% | 22+22.4%121% | 18+32.3%117% | 14+56.6%165% | 8.7—205% | |
| General and administrative | 16+6.6%19.6% | 15−1.1%21.2% | 15+7.4%25.5% | 14+11.3%33.5% | 12+22.8%42.3% | 10+63.0%55.7% | 6.2+27.0%40.3% | 4.9−1.2%59.2% | 5.0—117% | |
| Operating expenses | 88−0.1%110% | 88+4.7%127% | 84+27.5%144% | 66+36.9%159% | 48+32.2%164% | 37+28.4%200% | 28+37.2%184% | 21+6.5%250% | 19—458% | |
| Operating income | −34—−42.0% | −34—−49.2% | −44—−75.4% | −39—−94.2% | −29—−100.0% | −25—−139% | −19—−124% | −18—−215% | −17—−399% | |
| Interest expense and finance costs | 5.2−0.9%6.5% | 5.3+1.3%7.6% | 5.2+28.9%8.9% | 4.1+12.6%9.8% | 3.6+0.9%12.2% | 3.6−1.2%19.6% | 3.6+100%23.4% | 1.8−60.5%21.8% | 4.6—107% | |
| Other non-operating income (expense) | −4.8—−6.0% | −3.9—−5.6% | −2.6—−4.4% | −5.3—−12.8% | −3.8—−13.0% | −3.5—−19.3% | −3.3—−21.1% | −3.3—−40.0% | −4.4—−104% | |
| Income before tax | −39—−48.1% | −38—−54.8% | −47—−79.8% | −44—−107% | — | — | — | — | — | |
| Income tax | 0.2—0.3% | −0.1—−0.2% | — | — | — | — | — | — | — | |
| Net income including minority interests | −39—−48.4% | −38—−54.6% | −47—−79.8% | −44—−107% | −33—−113% | −29—−158% | −22—−145% | — | — | |
| Net income attributable to shareholders | −39—−48.4% | −38—−54.6% | −47—−79.8% | −44—−107% | −33—−113% | −29—−158% | −22—−145% | −21—−255% | −21—−503% | |
| Earnings per share, basic | -0.83—— | -1.33—— | -2.04—— | -2.72—— | -2.30—— | -2.23—— | -17.10—— | -101.41—— | — | |
| Earnings per share, diluted | -0.83—— | -1.33—— | -2.04—— | -2.72—— | -2.30—— | -2.23—— | -17.10—— | -101.41—— | — | |
| Shares, weighted average (basic) | 47+64.6%— | 29+24.7%— | 23+40.6%— | 16+12.4%— | 14+11.9%— | 13+632%— | 1.8—— | — | — | |
| Shares, weighted average (diluted) | 47+64.6%— | 29+24.7%— | 23+40.6%— | 16+12.4%— | 14+11.9%— | 13+632%— | 1.8+499%— | 0.3+1.0%— | 0.3—— | |
| Balance sheet | ||||||||||
| Cash and cash equivalents | 51−3.5%62.4% | 53+12.7%60.8% | 47+11.2%59.9% | 42−4.4%61.9% | 44−40.9%70.2% | 74+64.2%86.0% | 45+162%66.7% | 17+52.3%63.5% | 11—— | |
| Short-term investments | — | — | — | — | — | 0−100%0.0% | 9.3—13.7% | — | — | |
| Receivables | 10+2.5%12.7% | 10+3.7%11.7% | 9.7+47.1%12.5% | 6.6+56.4%9.8% | 4.2+57.8%6.8% | 2.7−5.4%3.1% | 2.8+118%4.2% | 1.3—4.8% | — | |
| Inventory | 11−13.8%13.5% | 13−2.9%14.8% | 13+11.6%16.9% | 12+54.0%17.4% | 7.7+96.0%12.2% | 3.9−15.1%4.5% | 4.6+5.9%6.8% | 4.3—16.0% | — | |
| Other current assets | 3.4+33.7%4.1% | 2.5+20.2%2.9% | 2.1+4.1%2.7% | 2.0−37.7%3.0% | 3.2+44.2%5.2% | 2.2−2.9%2.6% | 2.3+599%3.4% | 0.3—1.2% | — | |
| Current assets | 76−3.2%92.8% | 78+8.8%90.2% | 72+14.9%91.9% | 62+5.7%92.0% | 59−29.0%94.4% | 83+29.4%96.3% | 64+177%94.7% | 23—85.4% | — | |
| Property, plant and equipment | 2.2−4.9%2.7% | 2.3+18.0%2.7% | 2.0+18.0%2.5% | 1.7+41.8%2.5% | 1.2+89.5%1.9% | 0.6−7.5%0.7% | 0.7−10.7%1.0% | 0.8—2.8% | — | |
| Right-of-use (leased) assets | 1.5−13.6%1.8% | 1.7−11.1%2.0% | 2.0+59.3%2.5% | 1.2—1.8% | — | — | — | — | — | |
| Other intangible assets | 1.4−21.9%1.7% | 1.7−17.9%2.0% | 2.1−15.2%2.7% | 2.5+8.5%3.7% | 2.3−11.7%3.7% | 2.6−10.4%3.0% | 2.9—4.3% | — | — | |
| Total assets | 81−6.0%100% | 87+10.9%100% | 78+15.0%100% | 68+8.5%100% | 63−27.7%100% | 86+27.3%100% | 68+149%100% | 27—100% | — | |
| Accounts payable | 2.3+7.5%2.8% | 2.1+28.8%2.5% | 1.7+8.7%2.1% | 1.5−36.5%2.3% | 2.4+270%3.9% | 0.7−79.4%0.8% | 3.2−7.3%4.7% | 3.4—12.6% | — | |
| Current liabilities | 18+15.2%22.1% | 16−8.1%18.0% | 17+36.8%21.7% | 12+17.3%18.3% | 11+60.1%16.9% | 6.6−1.6%7.6% | 6.7−29.8%9.9% | 9.6—35.1% | — | |
| Long-term debt | 56+35.3%68.4% | 41+1.5%47.5% | 41+1.5%51.9% | 40—58.8% | — | — | — | — | — | |
| Lease liabilities (non-current) | — | 1.5r1.4−11.8%1.7% | 1.7+41.7%2.2% | 1.2—1.8% | — | — | — | — | — | |
| Total liabilities | 75+29.2%92.2% | 58−1.8%67.1% | 59+10.5%75.8% | 54+26.2%78.9% | 42+13.4%67.9% | 37+1.3%43.3% | 37−9.7%54.4% | 41—150% | — | |
| Retained earnings | −398—−488% | −359—−414% | −321—−411% | −274—−404% | −230—−368% | −197—−227% | −168—−247% | −138—−506% | — | |
| Shareholders' equity | 6.3−77.8%7.8% | 28+50.7%32.9% | 19+32.0%24.2% | 14−28.8%21.1% | 20−59.0%32.1% | 49+58.3%56.7% | 31—45.6% | −138—−506% | −108—— | |
| Total liabilities and equity | 81−6.0%100% | 87+10.9%100% | 78+15.0%100% | 68+8.5%100% | 63−27.7%100% | 86+27.3%100% | 68+149%100% | 27—100% | — | |
| Shares outstanding | 45+13.1%— | 39+60.8%— | 24+27.8%— | 19+31.9%— | 15+0.6%— | 14+26.6%— | 11+3757%— | 0.3—— | — | |
| Cash-flow statement | ||||||||||
| Share-based compensation | 3.8−13.0%4.7% | 4.4−13.3%6.3% | 5.0+26.1%8.6% | 4.0+9.0%9.6% | 3.7+77.9%12.4% | 2.1+350%11.3% | 0.5+112%3.0% | 0.2+9.6%2.6% | 0.2—4.6% | |
| Cash from operating activities | −28—−35.2% | −42—−60.0% | −41—−69.9% | −41—−98.4% | −30—−103% | −24—−134% | −26—−165% | −20—−241% | −16—−386% | |
| Capital expenditure | −0.4—−0.6% | −1.0—−1.4% | −0.6—−1.0% | −0.9—−2.1% | −0.6—−2.1% | −0.2—−0.9% | −0.2—−1.3% | −0.1—−0.7% | −0.1—−2.7% | |
| Intangible assets bought | — | — | — | −1.0—−2.4% | — | — | −2.5—−16.2% | −1.5—−18.1% | — | |
| Cash from investing activities | 0.8−81.0%1.1% | 4.5—6.4% | −0.6—−1.0% | −1.9—−4.5% | −0.6−107%−2.1% | 9.1—50.1% | −12—−77.6% | −1.6—−18.8% | −0.1—−2.4% | |
| Debt issued | — | — | — | 40—96.6% | — | — | — | — | — | |
| Debt repaid | −42—−52.8% | — | — | −30—−72.4% | — | — | — | −13—−157% | — | |
| Shares issued | — | — | 46+34.7%79.3% | 34—83.1% | — | 45r0.0—246% | — | — | — | |
| Cash from financing activities | 26−40.2%32.1% | 43−6.9%62.1% | 46+13.3%79.2% | 41+6883%98.6% | 0.6−98.7%2.0% | 44−32.2%244% | 66+139%424% | 27+4.1%331% | 26—620% | |
| Exchange-rate effect on cash | — | — | — | — | — | 0.0—0.1% | −0.0—−0.0% | — | — | |
| Change in cash | −1.8−131%−2.3% | 5.9+19.4%8.6% | 5.0—8.5% | −1.9—−4.6% | −30−205%−103% | 29+3.8%160% | 28+372%181% | 5.9−39.9%71.7% | 9.9—232% | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 78+1.5%100% | 19−8.4%100% | 19−4.5%100% | 19+2.9%100% | 21*+18.2%100% | 21+9.1%100% | 20+25.5%100% | 19+11.5%100% | 18*+3.8%100% | 19—100% | 16—100% | 17—100% | 17*—100% | |
| Gross profit | 53+1.4%67.2% | 12−11.9%64.9% | 14−1.1%72.3% | 13+0.1%65.7% | 14*+22.6%65.9% | 14+8.6%67.5% | 14+27.4%69.8% | 13+10.4%67.6% | 11*−3.5%63.6% | 13—67.8% | 11—68.8% | 11—68.3% | 12*—68.4% | |
| Research and development | 8.8−3.5%11.3% | 1.6−31.7%8.5% | 2.7+23.6%14.1% | 2.3−7.8%12.3% | 2.1*+4.9%10.2% | 2.3+13.5%11.3% | 2.2−5.2%10.9% | 2.5+6.1%13.7% | 2.0*−24.4%11.5% | 2.1—10.9% | 2.3—14.4% | 2.4—14.4% | 2.7*—15.8% | |
| Selling and marketing | 61−2.6%77.9% | 13−13.7%68.6% | 16−2.5%85.2% | 17−0.4%86.8% | 15r14*+6.7%71.4% | 15r15−8.5%72.8% | 17+0.9%83.5% | 17−5.2%89.7% | 14*−18.7%79.1% | 16—86.9% | 17—104% | 18—106% | 17*—101% | |
| General and administrative | 15−3.1%19.2% | 3.0−23.9%15.8% | 4.1−1.6%21.1% | 4.2+8.6%21.9% | 3.8*+5.4%18.1% | 3.9+7.2%19.1% | 4.1+13.9%20.4% | 3.8+0.2%20.7% | 3.6*−11.4%20.3% | 3.7—19.4% | 3.6—22.5% | 3.8—23.1% | 4.1*—23.8% | |
| Operating expenses | 86−1.1%110% | 20−8.9%103% | 23+0.2%120% | 23+0.3%121% | 20*+4.2%97.8% | 22−3.1%104% | 23+2.4%115% | 23−3.2%124% | 20*−18.1%111% | 22—117% | 23—141% | 24—143% | 24*—141% | |
| Operating income | −34—−43.2% | −7.3—−38.5% | −9.3—−48.1% | −11—−55.2% | −6.6*—−31.9% | −7.6—−36.5% | −9.1—−45.0% | −10—−56.5% | −8.4*—−47.3% | −9.4—−49.4% | −12—−71.9% | −4.8—−29.1% | −12*—−72.2% | |
| Interest expense and finance costs | 7.9+60.8%10.1% | 2.1+74.8%11.1% | 2.1+74.7%10.8% | 2.1+68.4%10.8% | 1.6*+27.6%7.8% | 1.2−10.6%5.8% | 1.2−10.7%5.9% | 1.2−8.5%6.6% | 1.3*−4.6%7.3% | 1.3—7.1% | 1.3—8.3% | 1.3—8.0% | 1.3*—7.9% | |
| Other non-operating income (expense) | −7.8—−9.9% | −1.9—−10.1% | −1.9—−9.9% | −1.7—−8.9% | −2.2*—−10.8% | −1.0—−5.1% | −0.8—−4.0% | −0.7—−4.0% | −1.0*—−5.7% | −1.0—−5.3% | −1.0—−6.4% | −0.8—−5.0% | −0.6*—−3.6% | |
| Income before tax | −42—−53.1% | −9.2—−48.5% | −11—−58.1% | −12—−64.1% | −8.9*—−42.6% | −8.6—−41.6% | −9.9—−49.0% | −11—−60.5% | −9.4*—−53.0% | −10—−54.7% | −13—−78.3% | −5.7—−34.1% | — | |
| Income tax | 0.4—0.5% | 0.1—0.5% | 0.1+81.8%0.3% | 0.1+15.4%0.3% | 0.1*—0.7% | 0*—0.0% | 0.0—0.2% | 0.1—0.3% | — | — | — | — | — | |
| Net income including minority interests | −42—−53.6% | −9.3*—−49.1% | −11*—−58.4% | −12—−64.4% | −9.0*—−43.3% | −8.6*—−41.6% | −9.9*—−49.1% | −11—−60.8% | −9.2*—−52.2% | −10*—−54.7% | −13*—−78.3% | −5.7—−34.1% | −13*—−75.8% | |
| Net income attributable to shareholders | −42—−53.6% | −9.3—−49.1% | −11—−58.4% | −12—−64.4% | −9.0*—−43.3% | −8.6—−41.6% | −9.9—−49.1% | −11—−60.8% | −9.2*—−52.2% | −10—−54.7% | −13—−78.3% | −5.7—−34.1% | −13*—−75.8% | |
| Earnings per share, basic | — | -0.16—— | -0.20—— | -0.21—— | — | -0.19—— | -0.22—— | -0.25—— | — | -0.42—— | -0.51—— | -0.23—— | — | |
| Earnings per share, diluted | — | -0.16—— | -0.20—— | -0.21—— | — | -0.19—— | -0.22—— | -0.25—— | — | -0.42—— | -0.51—— | -0.23—— | — | |
| Shares, weighted average (basic) | 58+27.0%— | 58+27.0%— | 57+26.6%— | 57+26.5%— | — | 45+83.9%— | 45+83.9%— | 45+84.2%— | — | 25—— | 25—— | 25—— | — | |
| Shares, weighted average (diluted) | 58+27.0%— | 58+27.0%— | 57+26.6%— | 57+26.5%— | — | 45+83.9%— | 45+83.9%— | 45+84.2%— | — | 25—— | 25—— | 25—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 23—45.8% | 23−23.7%45.8% | 30−13.0%50.9% | 40−7.7%56.6% | 51−3.5%62.4% | 30+71.7%48.2% | 35+32.0%51.8% | 43+15.3%55.4% | 53+12.7%60.8% | 17—32.6% | 26—44.0% | 37—51.7% | 47—59.9% | |
| Receivables | 9.3—18.7% | 9.3−17.7%18.7% | 9.6−14.2%16.1% | 9.7−8.0%13.9% | 10+2.5%12.7% | 11+0.5%18.3% | 11+23.5%16.6% | 11+6.0%13.7% | 10+3.7%11.7% | 11—21.2% | 9.1—15.1% | 10.0—13.9% | 9.7—12.5% | |
| Inventory | 12—23.5% | 12+0.4%23.5% | 11−2.7%18.5% | 12−9.8%17.5% | 11−13.8%13.5% | 12−15.0%18.8% | 11−15.0%16.8% | 14−0.5%17.5% | 13−2.9%14.8% | 14—25.7% | 13—22.2% | 14—18.9% | 13—16.9% | |
| Other current assets | 1.1—2.1% | 1.1−69.9%2.1% | 3.4+6.6%5.6% | 2.8+0.4%4.1% | 3.4+33.7%4.1% | 3.5+74.4%5.7% | 3.2+47.4%4.7% | 2.8+47.1%3.7% | 2.5+20.2%2.9% | 2.0—3.8% | 2.1—3.6% | 1.9—2.7% | 2.1—2.7% | |
| Current assets | 45—90.1% | 45−20.4%90.1% | 54−10.3%91.2% | 64−7.8%92.0% | 76−3.2%92.8% | 56+27.0%91.0% | 61+18.9%89.9% | 70+11.4%90.3% | 78+8.8%90.2% | 44—83.2% | 51—84.9% | 63—87.2% | 72—91.9% | |
| Property, plant and equipment | 1.9—3.8% | 1.9−15.0%3.8% | 2.0−5.5%3.4% | 2.2−2.0%3.1% | 2.2−4.9%2.7% | 2.2−8.7%3.6% | 2.2−7.7%3.2% | 2.2−5.3%2.8% | 2.3+18.0%2.7% | 2.4—4.6% | 2.3—3.9% | 2.3—3.2% | 2.0—2.5% | |
| Right-of-use (leased) assets | 1.3—2.7% | 1.3−15.8%2.7% | 1.4−14.7%2.3% | 1.4−14.1%2.1% | 1.5−13.6%1.8% | 1.6−13.1%2.5% | 1.6−12.7%2.4% | 1.7−11.9%2.2% | 1.7−11.1%2.0% | 1.8—3.4% | 1.9—3.1% | 1.9—2.7% | 2.0—2.5% | |
| Other intangible assets | 1.1—2.2% | 1.1−26.1%2.2% | 1.2−24.5%2.0% | 1.3−23.1%1.8% | 1.4−21.9%1.7% | 1.5−20.7%2.4% | 1.5−19.7%2.3% | 1.6−18.8%2.1% | 1.7−17.9%2.0% | 1.8—3.5% | 1.9—3.2% | 2.0—2.8% | 2.1—2.7% | |
| Total assets | 49—100% | 49−19.6%100% | 60−11.5%100% | 70−9.5%100% | 81−6.0%100% | 62+16.2%100% | 68+12.2%100% | 77+7.5%100% | 87+10.9%100% | 53—100% | 60—100% | 72—100% | 78—100% | |
| Accounts payable | 2.4—4.8% | 2.4+0.9%4.8% | 2.9+65.6%4.8% | 3.9−2.7%5.6% | 2.3+7.5%2.8% | 2.4−4.3%3.9% | 1.7−24.8%2.6% | 4.0+19.2%5.2% | 2.1+28.8%2.5% | 2.5—4.7% | 2.3—3.8% | 3.4—4.7% | 1.7—2.1% | |
| Debt due within a year | 56—114% | 56—114% | — | — | — | — | 3.3—4.9% | — | — | — | — | — | — | |
| Current liabilities | 73—147% | 73+329%147% | 18−4.4%30.5% | 18+7.8%25.5% | 18+15.2%22.1% | 17+0.7%27.6% | 19+27.2%28.2% | 17+8.9%21.4% | 16−8.1%18.0% | 17—31.8% | 15—24.9% | 15—21.1% | 17—21.7% | |
| Long-term debt | — | — | 56+47.4%93.9% | 56+35.4%79.9% | 56+35.3%68.4% | 41+1.3%67.4% | 38−6.8%56.3% | 41+1.5%53.4% | 41+1.5%47.5% | 41—77.3% | 41—67.8% | 41—56.6% | 41—51.9% | |
| Lease liabilities (non-current) | — | — | — | — | — | — | — | — | 1.5r1.4−11.8%1.7% | — | — | — | 1.7—2.2% | |
| Total liabilities | 74—150% | 74+23.4%150% | 76+29.6%127% | 75+27.0%107% | 75+29.2%92.2% | 60+1.3%97.5% | 58+1.8%86.4% | 59+2.9%76.5% | 58−1.8%67.1% | 59—112% | 57—95.2% | 57—80.0% | 59—75.8% | |
| Retained earnings | −430—−870% | −430—−870% | −421—−705% | −410—−586% | −398—−488% | −389—−631% | −380—−563% | −370—−479% | −359—−414% | −350—−659% | −339—−563% | −327—−455% | −321—−411% | |
| Shareholders' equity | −25—−49.7% | −25−1678%−49.7% | −16−273%−26.6% | −5.2−129%−7.4% | 6.3−77.8%7.8% | 1.6—2.5% | 9.2+220%13.6% | 18+26.0%23.5% | 28+50.7%32.9% | −6.3—−11.8% | 2.9—4.8% | 14—20.0% | 19—24.2% | |
| Total liabilities and equity | 49—100% | 49−19.6%100% | 60−11.5%100% | 70−9.5%100% | 81−6.0%100% | 62+16.2%100% | 68+12.2%100% | 77+7.5%100% | 87+10.9%100% | 53—100% | 60—100% | 72—100% | 78—100% | |
| Shares outstanding | 45—— | 45+11.9%— | 45+13.3%— | 45+13.2%— | 45+13.1%— | 40+63.2%— | 40+60.4%— | 40+60.4%— | 39+60.8%— | 25—— | 25—— | 25—— | 24—— | |
| Cash-flow statement | ||||||||||||||
| Share-based compensation | 2.9−29.6%3.7% | 0.6−34.5%3.3% | 0.6−37.8%3.2% | 0.8−21.8%4.3% | 0.8*−25.4%3.9% | 1.0−11.7%4.6% | 1.0−9.6%4.9% | 1.0−5.3%5.6% | 1.1*−12.2%6.2% | 1.1—5.7% | 1.1—6.8% | 1.1—6.6% | 1.2*—7.3% | |
| Cash from operating activities | −34—−43.6% | −8.7*—−45.8% | −9.4*—−48.6% | −11—−58.6% | −4.9*—−23.3% | −5.7*—−27.6% | −7.9*—−39.1% | −9.7—−52.5% | −7.5*—−42.7% | −9.0*—−47.4% | −11*—−66.5% | −14—−86.6% | −11*—−65.0% | |
| Capital expenditure | −0.3—−0.4% | −0.0*—−0.0% | −0.1*—−0.3% | −0.1—−0.6% | −0.1*—−0.4% | −0.2*—−1.0% | −0.1*—−0.6% | −0.0—−0.2% | −0.3*—−1.5% | −0.1*—−0.6% | −0.3*—−1.9% | −0.3—−1.8% | −0.2*—−1.2% | |
| Cash from investing activities | 1.6+253%2.1% | 1.0*+226%5.4% | 0.2*+17.2%1.2% | 0.2+37.7%1.0% | 0.2*—0.9% | 0.3*—1.5% | 0.2*+204%1.0% | 0.1−97.1%0.7% | −0.2*—−1.1% | −0.1*—−0.6% | 0.1*—0.4% | 4.7—28.3% | −0.2*—−1.1% | |
| Shares issued | — | — | — | — | — | — | — | — | — | — | — | — | 0*—0.0% | |
| Cash from financing activities | 25−40.5%32.6% | −0.1*−325%−0.3% | −0.0*—−0.1% | −0.3—−1.6% | 26*−39.8%124% | 0.0*−75.5%0.1% | −0.0*—−0.0% | −0.1−307%−0.6% | 43*+194936%243% | 0.1*—0.5% | −0.0*—−0.0% | 0.1—0.3% | 0.0*—0.1% | |
| Change in cash | −7.1−157%−9.1% | −7.8*—−40.9% | −9.2*—−47.5% | −11—−59.3% | 21*−40.3%101% | −5.3*—−25.5% | −7.9*—−38.9% | −9.8—−53.1% | 35*—200% | −9.2*—−48.5% | −11*—−66.2% | −9.6—−57.7% | −11*—−65.9% | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
What TELA Bio, Inc. sells: revenue by product line, fiscal 2025#
As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.
Business segments
- Single reportable segment$80 M100%+16%
Countries and regions
- Non-US(total)$12 M15%+17%
Source: SEC annual report (XBRL data) · as of Dec 31, 2025
Where TELA Bio, Inc. operates: 2 countries#
Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue. 1 subsidiaries on file.
Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided
Events at TELA Bio, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Delisting notice 2 · Restructuring 1 · Directors and officers 9 · Material agreement 3 · Agreement ended 1 · New debt 1 · Unregistered share sale 1 · Shareholder vote 3 · Results announced 11
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Material agreement | 8-K | |
| Delisting notice | 8-K | |
| RestructuringDirectors and officers | 8-K | |
| Directors and officers | 8-K/A | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Directors and officersShareholder vote | 8-K | |
| Results announced | 8-K | |
| Directors and officersResults announced | 8-K | |
| Results announced | 8-K | |
| Delisting notice | 8-K | |
| Material agreementAgreement endedNew debtUnregistered share sale | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Directors and officersShareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 10, 2026
Acquisitions and funding#
7 private funding rounds before listing
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Jun 2019 | $11 M | No. 7 | $10 to $50 million | 15 | equity | SEC |
| Nov 2018 | $2 M | No. 6 | $2 to $10 million | 8 | equity | SEC |
| Oct 2017 | $15 M | No. 5 | $10 to $50 million | 1 | equity | SEC |
| Jan 2017 | $7 M | No. 4 | $2 to $10 million | 16 | equity | SEC |
| Oct 2014 | $45 M | No. 3 | $10 to $50 million | 29 | equity | SEC |
| Aug 2013 | $6 M | No. 2 | $2 to $10 million | 16 | equity | SEC |
| Dec 2012 | $16 M | No. 1 | $10 to $50 million | 15 | equity | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
From US state WARN notices and SEC 8-K restructuring filings, newest first.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | · | · | · | · | · | · | · | · | · | · | · | — |
| Announced | People | Kind | Where | Source |
|---|---|---|---|---|
| 20% of workforce | Restructuring planSEC 8-K | “The Plan will reduce the Company’s workforce by approximately 20%, from 201 full-time employees to 160 full-time employees, and is expected to be substantially completed during the…” | Filing |
Source: State WARN notices and SEC 8-K item 2.05
How TELA Bio, Inc. compares in Medical Equipment
- Market cap$52 M · higher than 29% of 8
- Revenue$80 M · higher than 50% of 19
- Net margin-53.6% · higher than 12% of 17
- Revenue growth15.8% · higher than 67% of 13
- Price / sales0.7× · lower than 67% of 7
- Price / book8.2× · lower than 0% of 7
- FCF yield-55.7% · higher than 0% of 7
- 🇺🇸 Streamex Corp.$52 M
- 🇺🇸 IRIDEX Corporation$12 M
- 🇨🇦 Profound Medical Corp.$240 M
- 🇺🇸 Electromed, Inc.$341 M
- 🇺🇸 Viemed Healthcare, Inc.$367 M
- 🇺🇸 Avita Medical, Inc.$525 M
Peer comparison · Medical Equipment
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| TELA Bio, Inc.🇺🇸 | $52 M | — | -53.6% | +15.8% |
| Avita Medical, Inc.🇺🇸 | $525 M | — | -42.6% | +11.5% |
| Viemed Healthcare, Inc.🇺🇸 | $367 M | 23.5× | 5.0% | +20.5% |
| Electromed, Inc.🇺🇸 | $341 M | 28.6× | 15.8% | +15.3% |
| Profound Medical Corp.🇨🇦 | $240 M | — | -137.4% | +50.8% |
| Streamex Corp.🇺🇸 | $52 M | — | — | +100.0% |
| IRIDEX Corporation🇺🇸 | $12 M | — | -6.9% | +8.2% |
| Beyond Air, Inc.🇺🇸 | $4 M | — | -407.6% | +107.6% |
| Varian Medical Systems🇺🇸 | $16.3 B | — | 8.5% | -1.8% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Streamex Corp.$52 M
- IRIDEX Corporation$12 M
- Profound Medical Corp.$240 M
- Electromed, Inc.$341 M
- Viemed Healthcare, Inc.$367 M
- Avita Medical, Inc.$525 M
Sources and freshness
- Market cap:
- Oct 6, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As of December 31, 2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at TELA Bio, Inc.? Verify and update this profile — free
Show TELA Bio, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.